Center-Authored Papers

Filters: Author is Krishnan, Amrita  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
A
Krishnan A, Pasquini MC, Logan B, Stadtmauer EA, Vesole DH, Alyea E, Antin JH, Comenzo R, Goodman S, Hari P et al..  2011.  Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial.. The lancet oncology. Abstract
D
Richardson PG, Soiffer RJ, Antin JH, Uno H, Jin Z, Kurtzberg J, Martin PL, Steinbach G, Murray KF, Vogelsang GB et al..  2010.  Defibrotide for the treatment of severe hepatic veno-occlusive disease and multiorgan failure after stem cell transplantation: a multicenter, randomized, dose-finding trial.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 16(7):1005-17. Abstract
H
D'Souza A, Pasquini M, Logan B, Giralt S, Krishnan A, Antin J, Howard A, Goodman S, Qazilbash M, Knust K et al..  2016.  Heavy/light chain ratio normalization prior to transplant is of independent prognostic significance in multiple myeloma: a BMT CTN 0102 correlative study.. British journal of haematology.
M
Cornell RF, D'Souza A, Kassim AA, Costa LJ, Innis-Shelton RD, Zhang M-J, Huang J, Abidi M, Aiello J, Akpek G et al..  2016.  Maintenance Versus Induction Therapy Choice on Outcomes after Autologous Transplantation for Multiple Myeloma.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. Abstract
P
Richardson PG, Riches ML, Kernan NA, Brochstein JA, Mineishi S, Termuhlen AM, Arai S, Grupp SA, Guinan EC, Martin PL et al..  2016.  Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure.. Blood. Abstract
Scott EC, Hari P, Sharma M, Le-Rademacher J, Huang J, Vogl D, Abidi M, Beitinjaneh A, Fung H, Ganguly S et al..  2016.  Post-Transplant Outcomes in High-Risk Compared with Non-High-Risk Multiple Myeloma: A CIBMTR Analysis.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 22(10):1893-1899. Abstract
S
Michaelis LC, Saad A, Zhong X, Le-Rademacher J, Freytes CO, Marks DI, Lazarus HM, Bird JM, Holmberg L, Kamble RT et al..  2013.  Salvage Second Hematopoietic Cell Transplantation in Myeloma.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. Abstract
Barba P, Burns LJ, Litzow MR, Juckett MB, Komanduri KV, Lee SJ, Devlin SM, Costa LJ, Khan S, King A et al..  2015.  Success of an International Learning Healthcare System in Hematopoietic Cell Transplantation: the American Society of Blood and Marrow Transplantation Clinical Case Forum.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. Abstract